Abstract
Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic treatment of osteoarthritis or rheumatoid arthritis (10 to 20 mg once a day) and for the treatment of primary dysmenorrhea (40 mg once a day). Valdecoxib is as efficacious as conventional non-COX-2 selective NSAIDs, but offers the advantage of a much better gastrointestinal tolerance. Valdecoxib has a prodrug that can be administered intravenously or intramuscularly (parecoxib, Dynastat) and has been developed for the short-term treatment of postsurgical pain.
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Arthritis, Rheumatoid / drug therapy
-
Cyclooxygenase Inhibitors / administration & dosage
-
Cyclooxygenase Inhibitors / therapeutic use*
-
Dysmenorrhea / drug therapy
-
Enzyme Inhibitors / administration & dosage
-
Enzyme Inhibitors / therapeutic use*
-
Female
-
Humans
-
Infusions, Intravenous
-
Injections, Intramuscular
-
Isoxazoles / administration & dosage
-
Isoxazoles / therapeutic use*
-
Osteoarthritis / drug therapy
-
Pain, Postoperative / drug therapy
-
Prodrugs
-
Sulfonamides / administration & dosage
-
Sulfonamides / therapeutic use*
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase Inhibitors
-
Enzyme Inhibitors
-
Isoxazoles
-
Prodrugs
-
Sulfonamides
-
valdecoxib